Laboratory of Developmental Biology

项目总结/摘要 出生缺陷研究实验室（BDRL）是唯一一个由NIH资助的胎儿组织储存库， 美国的科学家。HFT对于生物医学研究是不可替代的，因为动物和细胞 人类发展和疾病的模式并不完全符合或概括人类发展， 疾病此外，已经确定了人类和哺乳动物之间大脑和其他器官发育的差异。 动物模型动物和细胞模型可能不包含细胞类型的完全混合物或完全模拟 组织/器官结构发育基因的工程突变在模型中可能是胚胎致死的 使这些基因难以通过这种方法进行研究的生物。建立人源化小鼠模型 人类传染性、免疫性和肿瘤性疾病需要异种移植HFT。比较 需要模型系统和包括HFT在内的天然人体组织，以确保基于模型的结论 系统适用于人类生物学和医学。此外，人类特异性基因不能在 模型生物和成体干细胞不能用于研究所有的疾病，特别是那些有基础的疾病。 在产前发育中。因此，BDRL是一个重要的科学资源，以保持促进生物医学 研究进展，特别是因为替代商业实验室可能卷入争议 与高频交易指控有关近60年的记录和成功的BDRL一直是 通过与HFT一致提供与健康相关的科学服务， 遵守严格的道德和研究准则，没有违规行为。壮观的技术 生物学的进步，特别是基因组学的进步，极大地扩大了利用高频技术促进 新颖的见解。这些进展证实了实验室继续创新和承担 合作评估和协同证明新的实验方法，以最大限度地提高 HFT的科学效用该应用程序旨在开发超出核心基本目标的资源 系统收集和处理胎儿标本，以便将HFT和生物制剂分发给受体。我们 建议通过继续与合作者合作，以协同方式进一步开发研究资源 发展他们的研究，发展我们的专业知识和服务。同时，这有助于促进 实验室的认识，以增加受援国的招聘，以及加强研究进展， 人类发展和疾病的基础。

PROJECT SUMMARY/ABSTRACT The Birth Defects Research Laboratory (BDRL) is the only NIH-funded fetal tissue repository available to scientific recipients in the US. HFT is irreplaceable for biomedical research because animal and cellular models of human development and disease do not fully match or recapitulate human development and disease. Also, differences in brain and other organs in development have been identified between humans and animal models. Animal and cellular models may not contain the full mixture of cell types or fully mimic tissue/organ structure. Engineered mutations in developmental genes maybe embryonically lethal in model organisms rendering such genes intractable to study by this approach. Creation of humanized mice to model human infectious, immunological and neoplastic diseases requires xenografting of HFT. Comparison between model systems and native human tissue including HFT is required to ensure that conclusions based on model systems are applicable to human biology and medicine. Further, human-specific genes cannot be studied in model organisms and adult-stem cells cannot be used to study all disorders, especially those that have a base in prenatal development. The BDRL is therefore a crucial scientific resource to retain for facilitating biomedical research progress, especially since alternative commercial laboratories maybe embroiled in controversy related to accusations of trade in HFT. The near 60-year track record and success of the BDRL has been proven many times over from consistent provision of recipient-related scientific services with HFT, fully compliant with strict ethical and research guidelines, without transgression. Spectacular technological advances in biology, notably -omics have greatly expanded research opportunities for utilizing HFT to facilitate novel insights. These advances confirm the rationale for the laboratory to continue to innovate and undertake collaborations to evaluate and synergistically demonstrate novel experimental approaches to maximize the scientific utility of HFT. This application seeks to develop the resource beyond the core fundamental goal of the systematic collection and processing of fetal specimens for distribution of HFT and biologics to recipients. We propose to further develop the research resource by continuing to engage with collaborators to synergistically develop their research and develop our expertise and services. Concurrently, this serves to promote awareness of the laboratory to increase recipient recruitment, as well as enhance research progress into the bases of human development and disease.